← Home / Bio-Rad Laboratories, Inc. (BIO)
Stock Analysis
Bio-Rad Laboratories, Inc. (BIO)
BIO
BIO · Market data
321.44 -1.62%
Track BIO in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when BIO price is:
52W Range Position
81%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-02 16:46 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 339.75. Holding above 299.18 keeps the current thesis intact.
⚖️
✓
Fundamentals
Moderate / Negative
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
299.18
↗
Break Above
Confirmation improves above resistance.
339.75
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 299.18
Recent Company Events
SEC VERIFIED
Latest material filings
APR
30
●
Financial Results
HIGH
Bio-Rad Reports First -Quarter 2026 Financial Results
HERCULES, Calif.—April 30, 2026 -- Bio-Rad Laboratories, Inc.
8-K Filing • SEC EDGAR
What's Driving BIO?
📈 Technical recovery is improving
Momentum is Neutral. Watch 339.75 for confirmation and 299.18 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
Below 299.18
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
62.5
Price Chart
BIO — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Value
Value-oriented setup
Sales and book multiples are contained.
Market Cap
$8.7B
Company size
EV
$9.4B
Debt-adjusted value
P/E
11.4
Low multiple
P/S
3.3
Low sales multiple
P/B
1.3
Low book multiple
EV/Sales
3.6
Low sales multiple
EV/EBIT
162.7
Very high
P/FCF
24.3
Reasonable
FCF Yield
4.12%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Moderate
●
Profitability
Negative
≈
Cash Flow
Positive
⚖
Balance Sheet
Manageable
💵 Revenue
592.10M
≈ Moderate
📈 Net Income
-527.10M
↘ Negative
🧮 EPS (Basic)
-19.55
↘ Negative
Bio-Rad Laboratories, Inc.
Related Opportunities